Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.48 |
| ▸ | AGXT | P21549 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.38 |
| ▸ | DAO | P14920 | 1/20 | 0.38 |
| ▸ | TSPO | P30536 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 2/20 | 0.36 |
| ▸ | HTR2C | P28335 | 2/20 | 0.36 |
| ▸ | MAOB | P27338 | 1/20 | 0.36 |
| ▸ | MPO | P05164 | 1/20 | 0.36 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 2/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29700948 | 1.00 | IDO1 (0.48) | IDO1AGXTKDM4ESMN1; SMN2ALDH1A1 | |
| Hydrochloric Acid SCHEMBL17204528 | 0.98 | IDO1 (0.50) | IDO1AGXTKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL29618975 | 0.83 | PSEN1 (0.40) | IDO1AGXTALDH1A1FFAR1FFAR4 | |
| SCHEMBL1020440 | 0.83 | PSEN1 (0.40) | IDO1AGXTALDH1A1FFAR1FFAR4 | |
| SCHEMBL3076688 | 0.81 | CA3 (0.46) | IDO1AGXTMPOSLC6A4MAPT | |
| SCHEMBL6140760 | 0.80 | IDO1 (0.50) | IDO1AGXTKDM4ESMN1; SMN2ALDH1A1 | |
| SCHEMBL24136215 | 0.79 | FFAR1 (0.45) | FFAR1FFAR4TSPODRD3HTR2A | |
| SCHEMBL444029 | 0.79 | CYP2A6 (0.49) | IDO1ALDH1A1FFAR1FFAR4TSPO | |
| SCHEMBL2286658 | 0.79 | P2RX7 (0.38) | IDO1AGXTKDM4EALDH1A1HTR2A | |
| SCHEMBL4714190 | 0.79 | ADRA2B (0.44) | IDO1AGXTKDM4EALDH1A1FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 198 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107394267-B | Electrolyte and lithium ion battery | 湛江市金灿灿科技有限公司 | 2021-06-25 | — | — | CN | claimed |
| CN-107394267-A | Electrolyte and lithium ion battery | 湛江市金灿灿科技有限公司 | 2017-11-24 | — | — | CN | claimed |
| US-4822903-A | Fluorinated silica catalyst and preparation of aromatic/aliphatic nitriles in the presence thereof | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1989-04-18 | — | — | US | claimed |
| US-4438042-A | FROM AMIDES, FLUORINATE SILCEOUS CATALYSTS | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1984-03-20 | — | — | US | claimed |
| US-4436669-A | CYANATION, DECARBONYLATION, ACID CATALYSTS | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1984-03-13 | — | — | US | claimed |
| US-20250163039-A1 | HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF CANCER | BOEHRINGER INGELHEIM INT (DE) | 2025-05-22 | — | — | US | disclosed |
| EP-4452964-A1 | HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF CANCER | Boehringer Ingelheim International GmbH (DE) | 2024-10-30 | — | — | EP | disclosed |
| US-20240317686-A1 | RORyT MODULATOR, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) | 2024-09-26 | — | — | US | disclosed |
| CN-118339153-A | Heteroaromatic compounds for the treatment of cancer | 勃林格殷格翰国际有限公司 | 2024-07-12 | — | — | CN | disclosed |
| CN-117800874-A | Flexible crystal material of dibenzoacrylonitrile, preparation method and application thereof | 吉林大学 | 2024-04-02 | — | — | CN | disclosed |
| US-20240004296-A1 | RESIST UNDERLAYER FILM-FORMING COMPOSITION | NISSAN CHEMICAL CORPORATION (JP) | 2024-01-04 | — | — | US | disclosed |
| CN-117186011-A | APOBEC3G compound and application thereof in preparing antiviral drugs | 浙江师范大学 | 2023-12-08 | — | — | CN | disclosed |
| US-5136080-A | Intermediates for glutamate inhibitors | BURROUGHS WELLCOME CO. (US) | 1992-08-04 | — | — | US | disclosed |
| WO-1991016894-A1 | QUINOLIZINONE TYPE COMPOUNDS | ABBOTT LABORATORIES (US) | 1991-11-14 | — | — | WO | disclosed |
| EP-0372934-A2 | Pharmacologically active CNS compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-06-13 | — | — | EP | disclosed |
| US-4822903-A | Fluorinated silica catalyst and preparation of aromatic/aliphatic nitriles in the presence thereof | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1989-04-18 | — | — | US | disclosed |
| US-4504595-A | Fluorinated silica catalyst and preparation of aromatic/aliphatic nitriles in the presence thereof | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1985-03-12 | — | — | US | disclosed |
| US-4438042-A | FROM AMIDES, FLUORINATE SILCEOUS CATALYSTS | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1984-03-20 | — | — | US | disclosed |
| US-4436669-A | CYANATION, DECARBONYLATION, ACID CATALYSTS | RHONE-POULENC SPECIALITES CHIMIQUES (FR) | 1984-03-13 | — | — | US | disclosed |
| US-3979444-A | CENTRAL NERVOUS SYSTEM DEPRESSANTS, HYPOTENSIVES | THE UPJOHN COMPANY (US) | 1976-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163039-A1 | HETEROAROMATIC COMPOUNDS FOR THE TREATMENT OF CANCER | NRAS, KRAS, RB1 | IDO1 3669/4885AGXT 3079/4885KDM4E 2708/4885 |
| US-20240317686-A1 | RORyT MODULATOR, AND PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | RORC, RORB, RORA | IDO1 787/4885AGXT 1966/4885KDM4E 2668/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.